Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.6650
+0.0100 (1.53%)
At close: Mar 28, 2025, 4:00 PM
0.7900
+0.1250 (18.80%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Company Description
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.
It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma.
The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Citius Oncology, Inc.
| Country | United States |
| Founded | 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Leonard Mazur |
Contact Details
Address: 420 Lexington Avenue, Suite 2446 New York, New York 10170 United States | |
| Phone | 347-627-0058 |
Stock Details
| Ticker Symbol | CTOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001851484 |
| ISIN Number | US17331Y1091 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Chairman, Chief Executive Officer and President |
| Myron Z. Holubiak | Executive Vice Chairman and Secretary |
| Dr. Myron S. Czuczman M.D. | Chief Medical Officer |
| Jaime Bartushak | Chief Financial Officer and Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2025 | DEFA14C | Filing |
| Feb 24, 2025 | DEF 14C | Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 10-Q | Quarterly Report |
| Feb 12, 2025 | PRE 14C | Filing |
| Feb 6, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 10-K/A | [Amend] Annual report |
| Jan 7, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Dec 27, 2024 | 8-K | Current Report |